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ABSTRACT
Various attempts have been made to develop stem cell-
based therapy to alleviate type I diabetes using animal
models. However, it has been a question whether human
insulin produced from explanted cells is solely responsible
for the normoglycemia of diabetic animals. In this study,
we isolated neural crest-like stem cells from the human eye-
lid fat and examined their therapeutic potentials for
diabetes. The human eyelid adipose-derived stem cells
(HEACs) displayed characteristics of neural crest cells.
Using a two-step culture condition combined with nicotina-
mide, activin, and/or GLP-1, we differentiated HEACs into
insulin-secreting cells and examined in vivo effects of differ-
entiated cells by transplantation experiments. Following dif-
ferentiation in vitro, HEACs released insulin and c-peptide
in a glucose-dependent manner. Upon their transplantation
under kidney capsules of streptozotocin-treated immuno-
competent mice, we observed normalization of hyperglyce-
mia in 10 of 20 recipient mice until sacrifice after 2 months.
Only the human, but not the mouse, insulin and c-peptide
were detected in the blood of recipient mice. Removal of the
kidneys transplanted with HEACs resulted in a sharp
increase of blood glucose level. Removed kidney tissues
showed distinct expression of various human genes
including insulin, and colocalization of the human insulin
and the human nuclear protein in many cells. However,
they showed diminished or null expression of some immune-
related genes. In conclusion, human insulin alone produced
from eyelid-derived stem cells following differentiation into
insulin-secreting cells and transplantation could normalize
type I diabetes in mice. STEM CELLS 2009;27:1999–2008
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INTRODUCTION
Type I diabetes is caused by the autoimmune destruction of
pancreatic b cells. Whole pancreas transplantation is an ideal
treatment, but the availability of this organ is limited. Alter-
native sources have been sought in extrapancreatic tissues.
Bone marrow cells of mice were shown to differentiate into
insulin-secreting cells in vitro and could reduce the blood
glucose level of mice with hyperglycemia [1, 2]. Similar
normoglycemia was observed when in vitro differentiated
human cells were used. Embryonic stem cells could differen-
tiate into insulin-producing cells in vitro and reverse the
hyperglycemic state when transplanted into diabetic mice [3,
4]. Liver cells following gene manipulation have shown to
secrete insulin in vitro and ameliorate hyperglycemia when
transplanted into diabetic mice [5, 6]. Peripheral blood-
derived monocytes [7] or umbilical cord-derived mesenchy-
mal stem cells (MSCs) [8], after in vitro differentiation into
insulin-secreting cells, could reduce blood glucose levels
when transplanted into diabetic murines. Although these
studies demonstrated that transplantation of differentiated
cells could normalize hyperglycemia of diabetic animals, it
is not clear whether the donor cells themselves could synthe-
size insulin and release it into the blood of recipient animals.
In contrast, other studies have shown that cell transplantation
might lower the blood glucose level of the recipient via
supporting the regeneration of recipient b cells rather than
providing insulin synthesized by donor cells. When mouse
undifferentiated bone marrow cells [9, 10] or splenocytes
[11] were transplanted into diabetic mice, the cells could
reduce the hyperglycemia. Transplantation of human marrow
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stromal cells into diabetic mice has also been shown to
reduce hyperglycemia by supporting the regeneration of re-
cipient b cells [12]. Since regenerated b cells in a type I dia-
betic patient can again be damaged by autoimmune attacks,
recruitment of therapeutic cells that directly regulate the
blood glucose level of the patient following transplantation
is an important issue in treating type I diabetes.
Neural crest-derived cells in mammals are peculiar in that
although they originate from ectoderm, they can differentiate
into many mesodermal lineage-like tissues such as facial
muscle, cartilage, bone, adipose, arterial endothelial cells, and
neural cells [13]. Indeed, stem cells isolated from neural
crest-derived dental tissue can differentiate into mesodermal
cells such as muscle, cartilage, ectodermal neurons, and odon-
toblasts in vitro, and bone cells in vivo [14]. Furthermore,
cells from a molar are capable of differentiating into endoder-
mal cells such as hepatocytes in vitro [15]. It is possible that
neural crest-derived cells could also differentiate into insulin-
secreting cells, a lineage of endodermal cells, similar to
hepatocytes.
Many studies have demonstrated that human stem/progen-
itor cells could survive in the absence of immunosuppressors
following xenogeneic transplantation into the bodies of exper-
imental animals [16–18]. Using undifferentiated cells, these
studies have shown that transplanted cells could survive as
long as 13 months in immunocompetent animal bodies. Since
type 1 diabetes is caused by the immune attack against the
differentiated b cells, we have questioned whether differenti-
ated cells could also survive and physiologically function in
foreign bodies following xenogeneic transplantation.
In the present study, we isolated novel stem cells with
neural crest characteristics from human eyelid adipose tissue.
These cells could effectively differentiate into insulin-secret-
ing cells under our in vitro culture condition and normalize
the hyperglycemia of streptozotocin (STZ)-treated immuno-
competent mice upon transplantation. The reversal was
observed only when differentiated cells were transplanted,
was exclusively due to the human insulin from the grafts, and
persisted as long as 1 year without graft rejection.
MATERIALS AND METHODS
Human Eyelid Adipose-Derived Stem Cell Isolation
and Culture
The human eyelid adipose tissue was obtained from nine subjects
aged between 11 and 79 years (mean age, 46.8  6.5 years)
undergoing cosmetic surgery with informed consent. Fat tissues
were surgically dissected from the subcutaneous zone. All experi-
ments were approved by Institutional Review Boards of Seoul
Women’s University and Yonsei University. Adipose tissue was
treated with 0.075% type I collagenase (Gibco, Grand Island,
NY, http://www.invitrogen.com) in phosphate-buffered saline
(PBS) for 30 minutes at 37C with gentle stirring. Cell suspen-
sions were cultured in Dulbecco’s modified Eagle’s medium low
glucose (DMEM-LG) (Gibco) supplemented with 10% fetal
bovine serum (FBS) (HyClone, Logan, UT, http://www.hyclone.
com), 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 3.7 mg/
ml sodium bicarbonate at 5% CO2, 37
C. Medium was changed
twice a week. Cumulative population doubling at each subculture
was calculated by using the formula 2X ¼ NH/NI, where NI ¼ the
inoculum cell number, NH ¼ cell harvest number at confluence
(>80%), and X ¼ population doublings [19]. The population dou-
bling increase that was calculated was then added to the previous
population doubling level to yield the cumulative population dou-
bling level.
Flow Cytometric Analysis
After culture, 1  106 cells were transferred to DMEM-LG con-
taining 25% FBS and 10% dimethyl sulfoxide and frozen at
80C overnight followed by storing at 196C in a liquid nitro-
gen tank. Frozen cells were thawed at 37C in a water bath and
then cultured in DMEM-LG supplemented with 10% FBS. After
trypsinization, detached cells were resuspended and then
incubated with primary antibodies for 1 hour at 4C. For stage-
specific embryonic antigen (SSEA)-4 and TRA 2-54 staining,
fluorescein isothiocyanate (FITC)-conjugated secondary antibody
was used for labeling. After washing, cells were analyzed on
FACS Calibur flow cytometer equipped with Cell Quest software
(BD, Franklin Lakes, NJ, http://www.bdbiosciences.com). Mono-
clonal antibodies for flow cytometric analysis were purchased
from the following companies: HLA-ABC, HLA-DR, CD31,
CD106, CD90, CD59, CD49d, CD45, CD34, and CD44 (BD Bio-
sciences); SSEA-4, TRA 2-54 (Chemicon, Temecula, CA, http://
www.chemicon.com); CD105 (R&D Systems Inc., Minneapolis,
http://www.rndsystems.com); HLA-G (Novus Biologicals, Inc.,
Littleton, CO, http://www.novusbio.com); CD117 (Miltenyi Bio-
tec, Bergisch Gladbach, Germany, http://www.miltenyibiotec.
com).
RT-PCR
RNA was isolated using Tri-reagent (Sigma-Aldrich, St. Louis,
http://www.sigmaaldrich.com) according to the manufacturer’s
instructions. The purity of RNA was assessed by determining the
ratio of absorbance at 260 nm to that at 280 nm (>1.8). Reverse-
transcription polymerase chain reaction (RT-PCR) was performed
using a GeneAmp PCR system 2400 (PerkinElmer Life and Ana-
lytical Sciences, Boston, http://www.perkinelmer.com). Subse-
quent PCR reactions were performed using cDNA, primer pairs
(supporting information Table 1), and PCR mixture (Fermentas,
St. Leon-Rot, Germany, http://www.fermentas.com) according to
the manufacturer’s instructions. Human adult pancreatic mRNA
was purchased from Ambion (Austin, TX, http://www.ambion.
com). RNAs from human embryonic stem cells (CHA-3 cell line
at passage [p] 72) and neuroblastoma cells (SH-SY5Y) were
kindly donated by Prof. Lee (Pochon Cha University, Korea) and
Prof. Kim (Kyunghee University, Korea), respectively.
Immunocytochemistry
After culture in Lab-Tek chamber slides (Nunc, Rochester, NY,
http://www.nuncbrand.com), human eyelid adipose-derived stem
cells (HEACs) were washed with PBS and then permeabilized in
0.5% Triton X-100 for 10 minutes. Endogenous peroxidase activ-
ity was inactivated with 3% hydrogen peroxide for 15 minutes at
room temperature (RT). The slides were incubated in a blocking
solution, consisting of 2% bovine serum albumin (BSA) in PBS
for 1 hour at RT. Between each step, cells were washed with
0.1% BSA in PBS. Cells were incubated with primary antibodies
overnight at 4C. The primary antibodies against human proteins
are listed in supporting information Table 2. After labeling with
the primary antibody, cells were then incubated with biotinylated
goat anti-mouse or anti-rabbit IgG (DakoCytomation, Glostrup,
Denmark, http://www.dakocytomation.com) followed by horse-
radish peroxidase-conjugated streptavidin (DakoCytomation) for
20 minutes, respectively, at RT. Immunoreactivity was visualized
using 3,30-diaminobenzidine tetrahydrochloride (DakoCytomation)
and counterstained with Mayer’s hematoxylin. Cells were photo-
graphed under a microscope using bright-field illumination (Axi-
oskop2þ; Carl Zeiss, Jena, Germany, http://www.zeiss.com). For
staining of neuronal markers, cells were incubated with goat
anti-mouse FITC-conjugated secondary antibodies (1:128), goat
anti-rabbit FITC-conjugated secondary antibodies (1:80), or rabbit
anti-goat FITC-conjugated secondary antibodies (1:400) for
30 minutes. Immunoreactive cells were visualized by fluorescence
microscopy (Axioskop2þ; Carl Zeiss).
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Assessment of Multidifferentiation Potential
HEACs were cultured in various differentiation media and
assessed as previously described [20]. To induce adipogenic dif-
ferentiation, HEAC at p4 were cultured in an adipogenic medium
consisting of DMEM-LG, 10% FBS, 1 lM dexamethasone,
0.5 lM 3-isobutyl-1-methylxanthine, 0.05 mg/l human insulin,
and 200 lM indomethacin. After culture for 2 weeks, presence of
intracellular lipid droplets, indicative of adipocytes, was assessed
by oil red O staining. To induce osteogenic differentiation, cells
were cultured in an osteogenic medium consisting of DMEM-LG,
10% FBS, 0.1 lM dexamethasone, 100 mM b-glycerol phos-
phate, and 50 lM ascorbic acid-2-phosphate. After culture for 2
weeks, mineralization of accumulated calcium, indicating osteo-
genic differentiation, was assessed by von Kossa staining. To
induce chondrogenic differentiation, cells were cultured in a
chondrogenic medium consisting of DMEM high glucose
(DMEM-HG), 0.1 lM dexamethasone, 50 lg/ml ascorbic acid-2-
phosphate, 100 lg/ml sodium pyruvate, 40 lg/ml proline, 10 ng/
ml transforming growth factor b1 (R&D Systems), and 50 mg/ml
ITS premix (6.25 lg/ml insulin, 6.25 lg/ml transferrin, 6.25 lg/
ml selenious acid, 1.25 mg/ml BSA, and 5.35 mg/ml linoleic
acid; BD Biosciences). After culture for 3 weeks, chondrogenic
differentiation was assessed by Alcian blue staining.
Differentiation of HEACs into Insulin-Secreting
Cells In Vitro
HEACs at p3-p5 were plated on collagen-coated 48-well dishes
at 5  103 cells per well. They were then cultured in various
combinations consisting of NA group containing 10 mM nicotina-
mide (N) and 4 nM activin A (A; Peprotech, Rocky Hill, NJ,
http://www.peprotech.com), NG group containing nicotinamide
and 10 nM GLP-1 (G), AG group containing A and G, and NAG
group containing N, A, and G. During the first week of culture,
the cells were grown in DMEM-HG containing 10% FBS and
during the following 2 weeks, they were cultured in DMEM-LG
containing 10% FBS.
Measurement of Insulin and c-Peptide
To measure the amount of insulin and c-peptide released in vitro,
cells were treated with DMEM-LG containing 0.5% BSA for 12
hours, washed with PBS, and then stimulated by DMEM-HG for 2
hours at 37C. The amount of insulin and c-peptide released into
the media was measured using the human insulin and c-peptide
enzyme-linked immunosorbent assay (ELISA) kit (Mercodia, Win-
ston Salem, NC, http://www.mercodia.com) according to the manu-
facturer’s instructions. For the measurement of insulin and c-pep-
tide levels in blood, mice that fasted overnight were i.p. injected
with glucose (1.5 g/kg body weight [bw]). After 30 minutes, mouse
sera were taken by cardiac puncture and the level of human insulin
and c-peptide was measured. Cells of MIN6N8, a mouse pancreatic
cell line, were similarly cultured as above except that 1  105 cells
per well were seeded. Mouse insulin and c-peptide were released
into the media, and levels were determined using a mouse insulin
ELISA kit (Mercodia) and c-peptide ELISA kit (Yanaihara Inc.,
Shizuoka, Japan, http://www.yanaihara.co.jp).
Dithizone Staining
Cultured cells were incubated in 100 lg/ml dithizone solution at
37C for 15 minutes.
Transplantation of HEACs into STZ-Induced
Diabetic Mice
Female C57BL/6 mice (16-18 g, 6-8 weeks) were purchased from
the Samtako Bio (Osan, Korea, http://www.samtako.com). Mice
were maintained in accordance with the policies of the Institu-
tional Animal Care and Use Committee of Seoul Women’s and
Yonsei Universities. Experimental diabetes was induced by a sin-
gle i.p. injection of STZ (180 mg/kg bw) in 100 mM citrate
buffer (pH 4.5). After 7 days, the blood glucose level was mea-
sured using an ACCU-CHEK Active (Roche Diagnostics, Basel,
Switzerland, http://www. roche-applied-science.com) following a
10-hour fast. Diabetic mice with glucose level > 350 mg/dl were
randomly allocated to differentiated cell transplant group (DC, n
¼ 20), undifferentiated cell transplant group (UDC, n ¼ 20), and
a sham-operated group (n ¼ 20). Approximately, 1.5  106 cells
were transplanted under the left kidney capsule by direct insertion
using a 30-gauge needle at 15 days after STZ injection. Trypan
blue test showed that 96.9%  1.1% of cells were viable after
release from this needle. Differentiated and undifferentiated cells
were obtained by culture of HEACs for 3 weeks in the NAG con-
dition or without additives, respectively. Blood glucose level was
measured after a 10-hour fast. Nephrectomy of the graft-bearing
kidney was performed 2 months later and blood glucose was
monitored until death (n ¼ 3). Survival curves were prepared
using the Kaplan-Meier method and analyzed for a significant dif-
ference by the log-rank Mantel-Cox test using SPSS 12.0 statisti-
cal software (SPSS Inc., Chicago, http://www.spss.com).
Glucose Tolerance Test
Thirty-six days after transplantation, mice fasted overnight. Blood
was sampled at 0, 30, 60, 90, 120, and 150 minutes after i.p.
injection of glucose solution (1.5 g/kg bw).
Immunohistochemistry
Graft-bearing kidneys and pancreata were removed from normal
and DC mice at 2 months or 1 year after transplantation. Tissues
were fixed with 4% paraformaldehyde, embedded in paraffin, and
cut into 5-lm sections, followed by permeabilization with 0.5%
Triton X-100 in PBS (PBST) for 10 minutes. For antigen
retrieval, tissue sections immersed in 10 mM citrate buffer solu-
tion (pH 6.0) were placed in a microwave for 20 minutes. For
pancreata tissues, the sections were incubated in 0.1% horse
serum at RT for 20 minutes. Then the sections were incubated
overnight at 4C with anti-insulin monoclonal (1:250; Abcam)
antibody, biotin-labeled anti-mouse goat antibody, and then
horseradish peroxidase-conjugated streptavidin (Vectastatin ABC
Kit; Vector Laboratories, Burlingame, CA, http://www.vectorlabs.
com). Counterstaining was done with Mayer’s hematoxylin. For
graft-bearing kidney tissue sections, the sections were incubated
in 1% BSA in PBS at RT for 20 minutes. Then the sections were
incubated overnight at 4C with the following mixture of two
primary antibodies in PBST containing 1% BSA: anti-human
nuclear antigen monoclonal (1:100; Chemicon) and anti-insulin
polyclonal (1:100; Chemicon) antibodies. After washing, the sec-
tions were incubated with the following mixture of two secondary
antibodies for 1 hour at RT: Texas red-conjugated anti-rabbit
sheep antibody (1:200; Abcam) and FITC-conjugated anti-mouse
goat antibody (1:200). Cell nuclei were visualized by incubating
for 5 minutes with 1 lg/ml 40-60 diamidino-2-phenylindole in
0.1 M PBS. Imaging was visualized by fluorescence microscope
(Axioskop2þ; Carl Zeiss).
Statistical Analysis
Data were expressed as mean  SEM. Statistical significance was
analyzed by one-way analysis of variance test and t test using
SPSS 12.0. A P value < .05 was considered statistically
significant.
RESULTS
Stem Cell Properties of Human Eyelid
Adipose-Derived Cells
After 3-week culture of cells isolated from human eyelid adi-
pose tissues, plastic-adherent cells with unique morphology
were obtained and are referred to as HEACs. They exhibited
neuron-like bipolar morphology until the senescence at p14 or
p15 (Fig. 1A). Throughout the culture, they underwent an
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average of 36.3 doublings and produced 6.9  1016 cells (Fig.
1B). HEACs both at p2 and p14 expressed stem cell-specific
genes of OCT4, REX1, and SCF, endoderm-specific genes of
BMP4, AFP, GATA4, and HNF4A, and mesoderm/endoderm-
specific genes of vimentin (VIM) and CK18. They did not
express mesoderm-specific brachyury (T) and endoderm-spe-
cific BMP2 genes (Fig. 1C). Immunocytochemical analyses
showed that HEACs at p4 expressed stem cell-specific pro-
teins of TRA 1-60, SSEA-3, SSEA-4, and CD90, and other
proteins, but not proteins of CD31 and HLA-DR (supporting
information Fig. 1). HEACs cultured in appropriate differen-
tiation media showed adipogenic, osteogenic, or chondrogenic
differentiation potential (Fig. 1D). Flow cytometric analyses
revealed that HEACs were positive for the antigens of SSEA-
4, HLA-ABC, CD44, CD49d, CD59, CD90, and CD105,
weakly positive for TRA 2-54 and CD34, and negative for
HLA-G, HLA-DR, CD31, CD45, CD106, and CD117 anti-
gens (Fig. 2 and supporting information Table 2).
HEACs from p2 until p14 expressed ectoderm- or neural
progenitor-specific genes of NCAM, FGF5, and NES, neuron-
specific genes of TUBB3 and GAP43, neural crest-specific
genes of MSX1 and SNAI2, and glial cell-specific genes of
GALC and CNPase (Fig. 3A). They expressed a glial cell-spe-
cific GFAP gene only at p2. HEACs also expressed an astro-
cyte-specific S100 gene, and neuron-specific genes of SOX9,
MAP2, SYP, MBP, NEFM, and TFAP2A at p8 or later. How-
ever, HEACs at all passages did not express CD133 gene, a
neural progenitor and hematopoietic stem cell marker (Fig.
3A). Human neuroblastoma cell line showed distinct expression
of all of these genes. In comparison, human abdominal adi-
pose-derived MSCs at p3 did not significantly express any of
the above genes except FGF5 and NES. HEACs spontaneously
expressed a variety of neuronal proteins including b-tubulin III,
galactocerebroside (GalC), serotonin, glial fibrillary acidic pro-
tein (GFAP), and c-aminobutyric acid (GABA) (Fig. 3B).
However, their immunoreactivity with anti-GFAP and anti-
GABA antibodies reduced as the culture continued. HEACs at
all passages did not express proteins of tyrosine hydrogenase
and cholinergic acetyltransferase (Fig. 3B). These results sug-
gest that HEACs are neural crest-derived stem cells, which
retain many neural properties even after long-term culture.
Differentiation of HEACs into Insulin-Secreting
Cells In Vitro
Until 2 weeks of culture, no colony was observed in HEACs of
all groups. At three weeks, cells of only AG and NAG groups
formed islet-like aggregates (supporting information Fig. 2),
but cells of all groups including control group expressed
GLP1R, NEUROD1, PAX4, ISL1, GCK, CK19, PPY, and
HNF4A genes (Fig. 4A). In addition to these genes, HEACs of
all groups except the control expressed genes of GLUT1, PC1/
3, and SST. Those of NG, AG, and NAG groups expressed INS
and NEUROG3 genes. HEACs of AG and NAG groups
expressed genes of PDX1, NKX6.1, and GCG. However,
HEACs of NAG group showed higher expression levels of
PDX1, NEUROG3, INS, and NEUROD1 genes than those of
AG group. Gene expression profiles of HEACs in NAG group
were comparable to those of the human pancreas (Fig. 4A).
ELISA analyses showed that HEACs of the control group
(C) followed by stimulating with high (25 mM, HG) or low
(5.5 mM, LG) glucose concentration secreted 13.7  9.2 pg/
ml and 14.2  0.6 pg/ml of insulin into the media, respec-
tively (Fig. 4B). In contrast, HEACs of the NAG group
secreted 128.5  11.1 pg/ml of insulin with HG and 8.0 
2.5 pg/ml with LG media—values greater than those of the
control (a and b, p < .05). Similarly, HEACs of the control
group released 28.3  18.0 pg/ml of c-peptide with HG and
15.8  7.9 pg/ml with LG media (Fig. 4C). Those of the
NAG group released 342.7  70.5 pg/ml of c-peptide with
HG and 21.4  9.9 pg/ml with LG media—values greater
than those of the control (a and b, p < .05). When cells of
MIN6N8, a mouse pancreatic cell line, were challenged with
LG and HG conditions, they showed about fourfold increase
of insulin secretion as glucose concentration increased (sup-
porting information Fig. 3). These results demonstrate that
NAG combination is the best condition for the differentiation
of HEACs into insulin-secreting cells and that insulin secre-
tion by HEACs is dependent on the glucose concentration.
Immunocytochemical studies showed that HEACs of
NAG group were strongly positive for the human proinsulin,
insulin, and c-peptide (Fig. 4D). Cells in colony-forming areas
of NAG group also gave an intense staining with dithizone
(Fig. 4E).
Normalization of Diabetes in Mice by
Transplantation with HEACs
STZ-treated C57BL/6 mice received saline or cell transplant
under the kidney capsules. Of 20 mice that received HEACs
of NAG group (DC mice) from the above experiments,
10 mice showed normalized blood glucose level and survived
for longer than 60 days (Fig. 5A). Among them, eight mice
were sacrificed at 61 days. At the time of sacrifice, all mice
Figure 1. Stem cell properties of HEACs. (A): Morphology of
HEACs at p2 and p14. (B): Cumulative doubling number of HEACs
throughout ex vivo expansion. (C): Expression of stem cell-specific
genes by HEACs and hESs. (D): Differentiation potential of HEACs at
p4 into adipocytes, osteoblasts, and chondroblasts. Scale bar ¼ 500 lm.
Abbreviations: HEAC, human eyelid adipose-derived stem cell; hES,
human embryonic stem cell; NC, negative control; p, passage.
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showed blood glucose level ranging between 118 and 134 mg/
dl, slightly higher than the normal levels ranging between 108
and 123 mg/dl. Two mice were allowed to live up to one and
half years. The other 10 DC mice died within 53 days after
transplantation. Mice that received a transplant of saline
(sham) or undifferentiated HEACs (UDC) began to die by 10
days after transplantation and all 40 mice died within 43 days.
Body weight of the sham and UDC group mice gradually
decreased after transplantation (Fig. 5B). In contrast, body
weight of DC mice began to increase after 18 days. Body
weight of normal mice gradually increased. Following trans-
plantation, blood glucose levels of the sham and UDC group
mice gradually increased during 36 days (Fig. 5C). In contrast,
blood glucose level of DC mice decreased during 61 days,
reaching the level of normal mice. Following removal of the
left kidneys transplanted with HEACs from 3 DC mice at 61
days after transplantation, blood glucose level of these mice
markedly increased during the next 7 days. Glucose tolerance
tests were done for 10 DC mice showing normoglycemia at 36
days after transplantation, and showed that blood glucose levels
of both the normal and DC mice dropped to initial levels within
150 minutes, although DC mice showed higher glucose level
than the normal mice (Fig. 5D). The results demonstrate that
insulin-secreting cells differentiated from HEACs could
normalize type I diabetes in mice.
Regulation of Mouse Blood Glucose Level by
Human Insulin from Transplanted HEACs
ELISA analyses showed that the blood of five randomly cho-
sen DC mice after 61 days of transplantation contained near
background values of mouse insulin and c-peptide levels,
whereas that of normal mice exhibited 3.0  0.7 ng/ml of
mouse insulin and 4.1  0.9 ng/ml of mouse c-peptide
(Fig. 6A). However, DC mice showed 0.4  0.1 ng/ml of
human insulin and 0.8  0.2 ng/ml of human c-peptide
(Fig. 6B). Normal mice exhibited a small amount of human
insulin and human c-peptide in their blood. These results
clearly show that only human, but not mouse, insulin and
c-peptide were present in the blood of DC mice.
Kidneys of DC mice at 2 months (DcK1) or 1 year (DcK2)
after transplantation showed expression of human genes of
PDX1, NEUROG3, NKX6.1, GCK, PC1/3, GLUT1, INS, GCG,
GAPDH, and hAlu, most of which were also expressed by
HEACs cultured in NAG condition before transplantation
(Figs. 4A and 6C). In contrast, normal mouse kidneys never
showed expression of these human genes. Before and after dif-
ferentiation into insulin-secreting cells in vitro, HEACs consis-
tently expressed transcripts of the immune-related genes of
HLA-ABC, b2M, CD40, CD59, TAP1, and TAP2, but they did
not express HLA-DR, HLA-DM, CD80, and CD86—genes that
are involved in cell-mediated immune responses (Fig. 6D).
DcK1 and DcK2 showed a similar expression pattern, except
that b2M and CD40 genes were no longer expressed. In addi-
tion, DcK2 did not express HLA-ABC gene.
Many cells of kidneys of DC mice reacted in common with
both antibodies against insulin and human nuclear antigen
(Fig. 7). Pancreas of the same mice showed only a few insulin-
positive pancreatic islets, the size of which was greatly
diminished compared with the normal pancreas. These obser-
vations show that transplanted HEACs survived and actively
synthesized human insulin in the kidneys of immunocompetent
mice for 2 months after transplantation and that little regenera-
tion of mice b cells occurred in pancreas of DC mice.
DISCUSSION
The highlights of this study are the isolation of adult stem
cells from the human eyelid adipose tissue, successful differ-
entiation into insulin-producing cells in vitro, and normaliza-
tion of hyperglycemia in STZ-induced diabetic mice without
immunosuppressive agents following transplantation of these
insulin-producing cells.
Human tissue cells that were manipulated to differentiate
into insulin-secreting cells in vitro have been shown to lower
Figure 2. Flow cytometric analyses of human eyelid adipose-derived stem cells (HEACs). HEACs at passage 3 were strongly positive for
SSEA-4, HLA-ABC, CD44, CD49d, CD59, CD90, and CD105; weakly positive for TRA 2-54 and CD34; and negative for HLA-DR, CD31,
CD45, CD106, and CD117 antigens. Abbreviations: APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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the glucose level when transplanted into diabetic animals [7,
8, 21–23]. Some of these studies demonstrated the presence
of human insulin and/or c-peptide in blood of recipient ani-
mals, suggesting that donor cell might have participated in
lowering the blood glucose level [8, 23]. However, it is
obscure in these studies whether the recipients themselves
produced their own insulin responsible for the normoglyce-
mia. In the present study, we observed that only human, but
not mouse, insulin and c-peptide were detected in the blood
of DC mice recovered from hyperglycemia. Removal of the
HEAC-bearing kidneys from these mice resulted in the hyper-
glycemia. Expression of human b cell-specific genes, and
human insulin- and nuclear protein-positive cells, was found
in these kidneys. Regeneration of islets in the pancreata of the
same mice was not seen. Our observations clearly demon-
strate that insulin from human donor cells is solely responsi-
ble for the normalization of hyperglycemia.
HEACs exhibit some of the characteristics typical of
MSCs in terms of the mesodermal differentiation potential,
expression of CD90 and CD105, and null expression of
CD34, CD45, CD106, and HLA-DR in addition to a variety
of proteins [24, 25]. However, they are markedly different
from MSCs isolated from other adipose tissues. Undifferenti-
ated HEACs spontaneously express many neural cell-related
mRNAs and a variety of neural proteins such as GABA,
GalC, serotonin, b-tubulin III, and GFAP, most of which are
also observed in human neural crest cells [26] and in neuro-
blastoma cells. In contrast, MSCs from the trunk adipose tis-
sues do not show most of these neural cell-like characters
unless they are cultured in the neurogenic conditions consist-
ing of particular chemicals, growth factors, or neural tissues
[24, 27–30]. Undifferentiated MSCs from abdominal adipose
in the present study also did not express most of neural cell-
related mRNAs seen in neuroblastoma cells. HEACs are of the
bipolar neuronal shape, whereas other MSCs are spindle
shaped. The origin of cell sources may explain the difference
between HEACs and other adipose-derived MSCs. In mice, it
has been observed that the cephalic neural crest cells produce a
subset of facial adipocytes but do not contribute to adipocytes
at the truncal level during normal development [31]. Although
embryonic truncal adipocytes may arise from MSCs derived
from truncal neural crest, these MSCs appear to be replaced by
as-yet-unidentified cells during later development [32]. Wnt-1
lineage tracing analysis has also demonstrated that mouse trun-
cal adipose-derived MSCs do not represent a neural crest-
derived population residing in adult adipose [33]. Based upon
these findings, it is concluded that HEACs are neural crest-
derived multipotent stem cells that are distinguished from trunk
adipose-derived MSCs. Given that mesoderm-like structures
including muscles, cartilages, bones, and arterial endothelial
cells in the head and neck are derived from cranial neural crest
cells [13], mesodermal differentiation potency of HEACs fur-
ther supports their origin from neural crest.
In vitro differentiated HEACs successfully engrafted in the
kidneys of half of the immunocompetent mice for 2 months or
longer. Similar engraftment of xenogeneic transplants over-
coming immune attack has been observed in a variety of
human cells and animal models. Although the tolerance across
the immune barrier is not absolute [34], the engraftment has
been explained by the low level of HLA class I, and the ab-
sence of HLA class II [18], CD80 and CD86 molecules [35],
all of which play key roles in T-cell-mediated immune
response. We also observed that differentiated HEACs as well
as undifferentiated ones did not express HLA-DR, HLA-DM,
CD80, and CD86 genes. Moreover, mouse kidneys transplanted
with differentiated HEACs showed little expression of human
b2M gene, which is a component of HLA-ABC and CD40 gene,
a costimulatory factor on antigen-presenting cells. These char-
acteristics might enable HEACs to overcome the T-cell-medi-
ated graft rejection following xenotransplantation. MSCs are
known to modulate the intensity of an immune response by in-
hibiting antigen-specific T-cell proliferation and cytotoxicity,
and have immunosuppressive activities via diverse soluble fac-
tors [36]. Whether HEACs could exhibit similar immunosup-
pressive activities remains in question. In the present study,
however, half of DC mice failed to recover from hyperglyce-
mia. HEACs in these mice might have been rejected by
immune attack or could not secrete enough amount of insulin.
The mechanism of the immune privilege of HEACs warrants
further investigation.
We successfully differentiated HEACs into insulin-secret-
ing cells in vitro. Since we did not use any insulin that might
be absorbed by cells during in vitro culture [37, 38], the insu-
lin that appeared in the media was de novo synthesized and
secreted by HEACs. The amount of c-peptide released into
the media was comparable with that released by pancreatic
islet cells [39]. Unique properties of HEACs expressing many
genes that play important roles in pancreatic differentiation
and/or insulin secretion most likely play a role in the success-
ful differentiation of HEACs into insulin-secreting cells.
Many of pancreatic genes such as NEUROD1, ISL1, PAX4,
NES [40], HNF4A [41], GLP1R [42], and GCK [43] are also
Figure 3. Neural properties of human eyelid adipose-derived stem
cells (HEACs). (A): Expression of neuron-related genes by HEACs at
p2, p8, and p14. (B): Immunocytochemistry of HEACs at p4, p8, and
p12. Scale bar ¼ 500 lm. Abbreviations: AA, human abdominal adi-
pose-derived stem cells at p3; NB, neuroblastoma cells; p, passage.
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expressed in cells of the nervous system. Previously, brain-
derived neural progenitor cells were shown to differentiate
into b-cell-like insulin-positive cells in vitro [44]. Conversely,
mouse adult pancreas could generate multiple cell types with
phenotypic characteristics of neurons and glial cells as well as
insulin-producing b-like cells in vitro [45, 46]. Similarities of
regulatory genes involved in both neural and b-cell differen-
tiation pathways may enable ectoderm- and pancreas-derived
stem cells to transdifferentiate.
Cytokine mixture also seems to contribute to efficient dif-
ferentiation of the HEACs. Nicotinamide enhances in vitro
differentiation of human fetal pancreatic cells, favoring the
expression of insulin gene [47]. Activin A [48] and GLP-1
[49] facilitate b-cell differentiation and potentiate glucose-de-
pendent insulin secretion of fetal and adult pancreatic cells.
We found that a mixture of all three compounds was optimal
to enable the differentiation of HEACs into insulin-secreting
cells. Lowering the glucose concentration during the last dif-
ferentiation stage following high concentration treatment was
shown to increase insulin secretion from embryonic stem cells
[50] and to increase the expression of b-cell-related genes in
neural progenitor cells [43]. Collectively, unique properties of
HEACs, combination of selected cytokines, and two-step cul-
ture method might cooperatively work, resulting in the efficient
differentiation of HEACs into insulin-secreting cells in vitro.
CONCLUSION
In conclusion, our results demonstrate that differentiated
HEACs could directly regulate blood glucose levels in dia-
betic mice by releasing human insulin, rather than supporting
Figure 4. Differentiation of human eyelid adipose-derived stem cells at passage 3 into insulin-secreting cells in vitro. After culture in various
differentiation conditions, cells were analyzed by dithizone staining (A), expression of genes (B), enzyme-linked immunosorbent assay for the
secretion of insulin (C) and c-peptide (D), and immunocytochemistry (E, 100). Scale bar ¼ 500 lm. a and b, p < .05. Abbreviations: AG,
activin A and GLP-1; C, control; Conc, concentration; hPan, human pancreas total RNA; NA, nicotinamide and activin A; NAG, nicotinamide,
activin A, and GLP-1; NG, nicotinamide and GLP-1.
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Figure 5. Physiological responses of diabetic mice to human eyelid adipose-derived stem cell transplantation. Following injection with saline
(Sham), UDC, or DC, (A) survival rate, (B) body weight, (C) blood glucose levels, and (D) glucose tolerance test were determined in 10 DC
mice that showed normoglycemia after 36 days. Data are shown as mean  SEM. Abbreviations: DC, differentiated cell transplant group; Mins,
minutes; UDC, undifferentiated cell transplant group.
Figure 6. Roles of human eyelid adipose-derived stem cells (HEACs) transplanted into immunocompetent mice. (A): Mouse and (B) human
insulin and c-peptide in the sera of normal and DC mice (n ¼ 5). *, p < .05. (C): Human genes expressed in kidneys of normal and DC mice.
(D): Expression of human immune genes by HEACs in vitro and in vivo. Abbreviations: C, control; DC, differentiated cell transplant group.
the regeneration or repopulation of mouse b cells. These find-
ings may be useful when considering the clinical application
of HEACs to diabetes mellitus and neural diseases.
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